A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B
Viruses · 2023
DOI: 10.3390/v15030724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Tanawat Geeratragool und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
International guidelines for hepatitis B infection (HBV) recommend initiating antiviral treatment based on viral replication with inflammation or fibrosis. HBV viral loads and liver fibrosis measurements are not widely available in resource-limited countries.
Aim
To develop a novel scoring system for the initiation of antiviral treatment in HBV-infected patients.
Methods
We examined 602 and 420 treatment-naïve, HBV mono-infected patients for derivation and validation cohorts. We performed regression analysis to identify parameters associated with the initiation of antiviral treatment based on the European Association for the Study of the Liver (EASL) guidelines. The novel score was developed based on these parameters.
Results
The novel score (HePAA) was based on HBeAg (hepatitis B e-antigen), the platelet count, alanine transaminase, and albumin. The HePAA score showed excellent performance, with AUROC values of 0.926 (95% CI, 0.901–0.950) for the derivation cohort and 0.872 (95% CI, 0.833–0.910) for the validation cohort. The optimal cutoff was ≥3 points (sensitivity, 84.9%; specificity, 92.6%). The HePAA score performed better than the World Health Organization (WHO) criteria and the Risk Estimation for HCC in Chronic Hepatitis B (REACH-B) score, and it performed similarly to the Treatment Eligibility in Africa for HBV (TREAT-B) score.
Conclusions
The HePAA scoring system is simple and accurate for chronic hepatitis B treatment eligibility in resource-limited countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
- Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
ORCID-Profile: Tanawat Geeratragool, Pisit Tangkijvanich, Phunchai Charatcharoenwitthaya
Zitieren
APA
Geeratragool, T., Tangkijvanich, P., Nimanong, S., Chainuvati, S., Charatcharoenwitthaya, P., Tanwandee, T., & Chotiyaputta, W. (2023). A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B. Viruses. https://doi.org/10.3390/v15030724
Vancouver
Geeratragool T, Tangkijvanich P, Nimanong S, Chainuvati S, Charatcharoenwitthaya P, Tanwandee T, et al. A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B. Viruses. 2023. doi:10.3390/v15030724
BibTeX
@article{Geeratragool2023,
author = {Geeratragool, Tanawat and Tangkijvanich, Pisit and Nimanong, Supot and Chainuvati, Siwaporn and Charatcharoenwitthaya, Phunchai and Tanwandee, Tawesak and Chotiyaputta, Watcharasak},
title = {A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15030724}
}
EUVIMED